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Recent decades have seen dramatic changes in the management of prostate cancer based on novel research findings.
Prostate-specific antigen (PSA) screening has been introduced, and then recently modified to include new strategies
and biomarkers. Management of advanced disease has been transformed by the rapid introduction of new agents.
We have moved from a “one-size-fits-all” approach in prostate cancer management to multidisciplinary strategies
tailored to the individual patient and his specific cancer. This editorial marks the launch of the article collection
Spotlight on prostate cancer (http://www.biomedcentral.com/bmcmed/series/SPR), and here, guest editors Sigrid
Carlsson and Andrew Vickers give an overview of the past, present, and future of prostate cancer research and
management.
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Introduction
In the nineteenth century, prostate cancer was described
as a “very rare disease” [1]. It is now the most common
male cancer, and the second or third most common cause
of cancer-related death in men in the US and in Europe
[2,3]. Our new series, Spotlight on prostate cancer, will ad-
dress a broad range of research and clinical topics related
to this common and important public health challenge.
We welcome submissions of research articles covering
prostate cancer epidemiology and prevention, screening
and risk stratification, disease management and new ther-
apies, biomarkers, molecular genomics, and translational
studies.
During the past three decades, we have witnessed
tremendous shifts in the way that we approach prostate
cancer. The introduction of prostate-specific antigen
(PSA) screening dramatically altered the presentation of
the disease, but we are now moving away from a “one-
size-fits-all” approach to new ways of individualizing
screening. Better understanding of prostate cancer biol-
ogy has led to the introduction of several new agents for
advanced disease, transforming what had previously* Correspondence: vickersa@mskcc.org
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article, unless otherwise stated.been a relatively barren field. Marker research has rap-
idly developed, with novel genomic markers now identi-
fying the molecular drivers of aggressive disease. We are
less aggressive in our approach to low-risk disease, mov-
ing away from radical treatment toward an increased use
of active surveillance, while becoming more aggressive
in attempting to control high-risk tumors. Instead of
administering hormonal treatment alone, we also attack
the tumor-invaded organs with surgery or kill the cancer
cells with radiation.
Are we on the way to solving the quandary of prostate
cancer, eloquently expressed by Dr. Willet Whitmore as:
“Is cure necessary in those for whom it is possible, and
is cure possible in those for whom it is necessary?”.
Every approach involves harms and benefits. Every
strategy can be debated. The intricacies and challenges
of trying our best to understand and manage this disease
continue to puzzle and to fascinate us. This new series,
Spotlight on prostate cancer, will include commentaries
as well as debate and opinion pieces.
Although knowledge of the etiology of prostate cancer is
still an area of investigation, evidence of nutritional and
dietary targets for primary prevention is accumulating. In
the review Nutrition, dietary interventions and prostate
cancer: the latest evidence, Lin and colleagues provide an
overview of recent literature on the possible influences of
diet and nutrients on prostate cancer outcomes [4].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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how best to screen, continues. We have witnessed the
rise of screening with PSA. We have observed the rapid
and dramatic increased incidence of the disease in the
US, followed by a decrease in prostate cancer mortality
[2], after the widespread implementation of PSA testing,
together with improvements in treatment [5]. We have
followed the success of large-scale European screening
trials that demonstrate a benefit of screening on prostate
cancer mortality [6,7].
Every other year or so we read updated and conflicting
guidelines [8], with the United States Preventive Services
Task Force (USPSTF), as the outlier, now recommending
against the use of routine screening [9].
In the commentary Prostate-specific antigen based
screening: Controversy and guidelines, Kim and Andriole
review the four largest randomized trials of screening
and treatment and provide some reasons why these
studies yielded apparently conflicting results [10]. Some
readers may interpret the results of the screening trials
as conflicting; the European ERSPC trial [6] indicating
“yes, screening works” and the US-led PLCO trial [11]
indicating “no, it does not”. Some could make the same
claim about the trials of radical prostatectomy versus
watchful waiting; the Scandinavian SPCG-4 trial [12] in-
dicating “yes, radical prostatectomy works” and the US
PIVOT trial [13] indicating “no, it does not”.
In our view, however, it is not a question of whether
screening and treatment work or do not work. The
question is: For which men, and in which situations,
might they work, when used appropriately and in a risk-
stratified manner?
The settings in which these four studies took place
played important roles. While the American population
was being heavily screened - essentially changing the
question of the PLCO away from an evaluation of the
effects of screening versus no screening - the European
control population remained largely unscreened, and
concomitantly, screening was shown to reduce prostate
cancer mortality. Men in the Scandinavian population in
SPCG-4 had clinically palpable, higher-risk disease, and
surgery was abandoned for men with positive nodes;
men in the American population in the PIVOT trial had
mainly PSA-detected, lower-risk disease, were older, and
surgery was more aggressive.
Owing to the heterogeneity of the disease, risk stratifi-
cation has become an important aspect of screening,
diagnosis, management, and treatment of prostate can-
cer. With personalized medicine, we attempt to tailor
the right treatment, for the right patient, at the right
time. Modern management of prostate cancer now in-
cludes active surveillance, that is, monitoring the disease
and delaying curative intervention until signs of disease
progression. Robot-assisted radical prostatectomy is nowmore commonly performed than open procedures. Our
approach to high-risk disease is multidisciplinary, and
we continue to make progress in the treatment of
advanced prostate cancer with the advent of new drugs
for castration-resistant disease, and finding the most
effective sequence in which to administer them. Reports
on prostate cancer management and treatment are
encouraged and will be welcome in Spotlight on prostate
cancer.
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